<DOC>
	<DOCNO>NCT02077556</DOCNO>
	<brief_summary>The purpose study understand effect everolimus tacrolimus pharmacokinetics ( pk ) patient receive de novo kidney transplant .</brief_summary>
	<brief_title>Effect Everolimus Pharmacokinetics Tacrolimus Renal Transplant Patients</brief_title>
	<detailed_description>Multidrug immunosuppression regimens synergistic effect allow use low dos individual agent . These regimen generally include calcineurin inhibitor ( CNIs : cyclosporine tacrolimus ) , mammalian target rapamycin ( mTOR ) inhibitor ( everolimus sirolimus ) , corticosteroid . CNIs mTOR inhibitor substrates cytochrome P450 3A4 ( CYP3A4 ) P-glycoprotein ( P-gp ) ; addition , cyclosporine inhibitor CYP3A4 P-gp . Therefore , concomitant administration drug may alter serum level . It remain evaluated whether pharmacokinetics clinical efficacy tacrolimus affect regimen contain everolimus clinical practice effect ABCB1、CYP3A4、CYP3A5、POR genetic polymorphism two Drugs . Mycophenolate mofetil ( MMF ) effect pharmacokinetics tacrolimus ; therefore , MMF use control understand effect everolimus pharmacokinetics tacrolimus patient receive de novo kidney transplant . The effect ABCB1、CYP3A4、CYP3A5、POR genetic polymorphism two Drugs also assess .</detailed_description>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Inclusion criterion : De novo kidney transplant 20 65 year old aspartate aminotransferase/alanine aminotransferase within 2 time upper limit normal range Exclusion criterion : Pregnancy Tuberculosis Hepatitis B C carrier status Human immunodeficiency viruspositive status Retransplantation multiorgan transplantation History rheumatoid arthritis Use drug might enhance inhibited CYP3A4 Pgp activity</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>tacrolimus , everolimus , pharmacokinetics , drug interaction</keyword>
</DOC>